Extended phase I evaluation of vincristine, Irinotecan, temozolomide, and antibiotic in children with refractory solid tumors

Pediatric Blood and Cancer

Volumn 54, Issue 7, 2010, Pages 909-915

  McNall Knapp, René Y ^a   Williams, Cydni N ^a   Reeves, Elaine N ^a   Heideman, Richard L ^b   Meyer, William H ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Irinotecan; Phase I; Temozolomide; Vincristine

Indexed keywords

CEFPODOXIME; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SCREENING; EPENDYMOMA; EWING SARCOMA; FEMALE; FEVER; GLIOMA; HEPATOBLASTOMA; HUMAN; HYPOKALEMIA; KIDNEY TUMOR; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; NEUTROPENIA; OPTIC NERVE GLIOMA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA; SARCOMA; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; HUMANS; INFANT; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; VINCRISTINE; YOUNG ADULT;

EID: 77951734314     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22460     Document Type: Article

References (24)

1. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 1997;8:313-322. (Pubitemid 27204948)
2. Houghton PJ, Cheshire PJ, Hallman JD2, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
3. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423-431. (Pubitemid 27158067)
4. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-4118.
5. Vassal G, Pondarre C, Boland I, et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 1998;80:271-280. (Pubitemid 28206042)
6. Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003;21:3844-3852. (Pubitemid 46606240)
7. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
8. Mugishima H, Matsunaga T, Yagi K, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol 2002;24:94-100. (Pubitemid 34150547)
9. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II windowtrials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 2007;25:362-369. (Pubitemid 350002984)
10. Turner CD, Gururangan S, Eastwood J, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience. Neuro-Oncol 2002;4:102-108. (Pubitemid 34285064)
11. Vassal G, Couanet D, Stockdale E, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: A joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 2007;25:356-361. (Pubitemid 350002983)
12. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group study. J Clin Oncol 2007;25:4622-4627. (Pubitemid 350035322)
13. Vassal G, Giammarile F, Brooks M, et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 2008;44:2453-2460.
14. Wagner LM, Crews KR, Stewart CF, et al. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer 2008;50: 201-207.
15. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patient with refractory solid tumors. J Clin Oncol 2006;24:563-570. (Pubitemid 46630418)
16. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840-848. (Pubitemid 38198882)
17. Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24:5271-5276. (Pubitemid 46631373)
18. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-139. (Pubitemid 44958268)
19. Thompson J, George EO, Poquette CA, et al. Development, characterization, and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother Pharmacol 2001;47:211-221. (Pubitemid 32640755)
20. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002;8:2202-2209. (Pubitemid 34753591)
21. Anderson P, Aguilera D, Pearson M, et al. Outpatient chemotherapy plus radiotherapy in sarcomas: Improving cancer control with radiosensitizing agents. Cancer Control 2008;15:38-46. (Pubitemid 351481990)
22. Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A new approach to Neuroblastoma Therapy Consortium study. J Clin Oncol 2009;27:1290-1296.
23. Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol 2009;27:abstr 10017.
24. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression. J Clin Oncol 2008;26:abstr 10013.